Drug intelligence / Profile preview

amoxicillin + clavulanic acid (Rishab Healthcare)

Development stage
Unknown
Lead developer
Rishab Health Care
Modality
Small Molecules
Administration
Oral
01

Overview

Reclav 625 is a branded generic combination antibiotic containing amoxicillin (500 mg) and clavulanic acid (125 mg). Amoxicillin, a beta-lactam antibiotic of the penicillin class, works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Clavulanic acid is a beta-lactamase inhibitor that protects amoxicillin from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending its spectrum of activity to include many strains otherwise resistant to amoxicillin alone. Manufactured by Rishab Healthcare, it is indicated for the treatment of various bacterial infections, including pneumonia, sinusitis, urinary tract infections, and skin and soft tissue infections.

Brand names
Reclav 625Reclav625Reclav-625
Other names
amoxicillin/clavulanateco-amoxiclav
02

Targets

Class A BL (Class A beta-lactamase)Serine beta-lactamase (Class C and D)

Beyond the preview

Go deeper on amoxicillin + clavulanic acid (Rishab Healthcare).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clavulanic acid (Rishab Healthcare).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call